Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy man or woman~* Body mass index between 18 and 29.9 kg/m2~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract~* Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs~* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AZD1722 alone (Type: EXPERIMENTAL): 15 mg BID
- AD1722 with Renvela (Type: EXPERIMENTAL): AZD1722 15 mg BID and Renvela 800 mg TID

Based on this trial design, predict the completion outcome and termination type (if applicable).